Psychedelic Therapy Training for Counsellors in Canada (2026 Guide)

Canadian counsellors — Canadian Certified Counsellors (CCCs), Registered Clinical Counsellors (RCCs), Registered Counselling Therapists (RCTs), and counselling therapists in unregulated provinces — can train in psychedelic-assisted therapy and contribute meaningfully to multidisciplinary PAT teams. Counsellors cannot prescribe, administer, or apply through Health Canada's Special Access Program; their role is preparation psychotherapy, supported facilitation during dosing sessions, and integration. This guide covers the credential-specific scope rules, ketamine-assisted therapy as the most accessible entry point, CCPA and BCACC continuing-education recognition, training programs in Canada, and how counsellors integrate into supervised clinic models.

Key takeaways

• Canadian counsellors cannot prescribe, dispense, or administer any psychedelic medicine and cannot apply through Health Canada's Special Access Program [BCACC 2024]. Authority for prescribing and SAP applications rests with physicians and nurse practitioners.
• Counsellors can deliver preparation psychotherapy, support clients during dosing sessions within sanctioned programs, and lead integration psychotherapy [BCACC 2024; BCCSW; Gorman et al. 2021].
• Ketamine-assisted psychotherapy is the most immediately accessible PAT context for trained counsellors in Canada because ketamine is an approved medicine with off-label psychiatric prescribing under provincial-college rules; psilocybin and MDMA require Health Canada SAP authorization.
• CCPA's Continuing Education Trust System (effective January 2025) maintains the 36-hour-per-3-year requirement; trust-based renewal replaces mandatory CEC submission unless audited.
• TheraPsil's psilocybin and MDMA training programs offer 155 CCPA CE hours; Numinus's pathway is approved by CCPA, CPA, OPQ, and NBCC.

Can Canadian counsellors practice psychedelic-assisted therapy?

Atomic answer: Yes — within scope. Canadian counsellors operating under regulated designations (RCC in BC, RCT in Nova Scotia, CRPO RP in Ontario, OPQ permit holder in Quebec) and under voluntary credentials (CCPA-certified CCC, ACTA-affiliated counselling therapist in Alberta) can be trained members of a PAT team. They cannot prescribe, dispense, or administer any controlled substance, and they cannot apply to Health Canada's Special Access Program on a patient's behalf [BCACC 2024]. Within a sanctioned clinical-trial program or a SAP-authorized program led by a physician or nurse practitioner, counsellors can deliver preparation, support clients during dosing, and lead integration psychotherapy [BCCSW; Gorman et al. 2021].

The therapeutic alliance counsellors build is itself an outcome variable in PAT. A meta-analysis of 295 independent psychotherapy studies (over 30,000 patients) confirms therapeutic alliance as a robust predictor of psychotherapy outcomes [Flückiger et al. 2018]. In psilocybin trials specifically, stronger pre-session alliance predicted greater emotional breakthrough, mystical-type experience, and lower depression scores at 4 weeks, 6 months, and 12 months post-treatment [Murphy et al. 2022; Levin et al. 2024]. Phelps's foundational competency framework names empathetic abiding presence and trust enhancement among the six core competencies of psychedelic therapists [Phelps 2017] — competencies counsellors develop throughout their training.

Your credential, your pathway: CCC, RCC, RCT, and what each can do

Counsellor designations and scope rules vary across Canadian provinces. Knowing your designation, regulator, and provincial scope determines what training you need and where you can practise within PAT.

Restricted titles to apply correctly: Registered Psychotherapist is restricted in Ontario to CRPO registrants; Psychothérapeute is restricted in Quebec to OPQ permit-holders. Other counsellor titles are generally voluntary credentials rather than statutorily protected titles.

The College of Alberta Psychologists' June 2025 Psychedelic-Assisted Psychotherapy Practice Guideline states that "diagnosing the need for specific psychedelic treatments and prescribing psychedelic medicines are outside the scope of psychological practice and ultimately rest with a client's primary physician/psychiatrist and/or nurse practitioner" [CAP 2025]. The same logic applies to counsellors: prescribing and administration are outside scope; the therapeutic and integration components are within scope when delivered with appropriate training and supervision.

Ketamine-assisted therapy: the most accessible PAT context for counsellors today

Ketamine is a Health Canada-approved anaesthetic prescribed off-label for depression, anxiety, PTSD, and chronic pain. Unlike psilocybin and MDMA, ketamine does not require a Special Access Program application. This makes ketamine-assisted psychotherapy (KAT) the most immediately accessible PAT context for trained counsellors working alongside a prescribing physician or nurse practitioner.

Provincial rules govern the team and facility configuration:

• British Columbia — non-IV ketamine (IM, oral, sublingual, intranasal) can be administered in community settings under physician oversight per CPSBC's interim guidance (Version 1.3, August 2025) [CPSBC 2025]. RCCs operate as team members within these settings.
• Alberta — psychedelic-assisted psychotherapy must occur in a CPSA-accredited facility under psychiatrist or physician-in-consultation-with-psychiatrist oversight per the March 2026 CPSA ketamine guidance [CPSA 2026]. Counsellors can be members of the therapeutic team within these facilities.
• Manitoba — CPSM's January 2026 guidance establishes prescriber competency requirements; counsellors are not the prescribing authority but can be team members [CPSM 2026].
• Ontario — CPSO has not published a ketamine-specific policy as of May 2026; off-label prescribing falls under general standards.

A Canadian-led systematic narrative review of 17 KAP studies (603 participants) by University of Toronto researchers concluded that "ketamine administration should be followed by additional psychotherapy to facilitate the integration of ketamine-induced transpersonal experiences and promote patient acceptance of insights" [Drozdz et al. 2022]. The largest Canadian KAP effectiveness study to date (1,806 enrolled, 346 at 3 months, 94 at 6 months) across Toronto, Vancouver, and Fredericton documented sustained large effect sizes (Cohen's d 0.61–0.86 at 6 months) for depression, anxiety, and PTSD using a protocol that incorporates motivational interviewing and trauma-informed integration techniques delivered by counselling-credentialled team members [Yermus et al. 2024]. Wilkinson et al. (2017) showed in an open-label trial that adding 10 weeks of cognitive behavioural therapy after IV ketamine sustained antidepressant response in 75 percent of ketamine responders through 8 weeks — establishing counsellor-delivered psychotherapy as a relapse-prevention mechanism [Wilkinson et al. 2017].

Psilocybin and MDMA training: what SAP access means for your practice

Psilocybin and MDMA are restricted drugs under the Food and Drug Regulations. Patient access is available only through Health Canada's Special Access Program (SAP), which only physicians and nurse practitioners can apply through. Counsellors cannot submit SAP applications — BCACC's 2024 guidance is explicit: "Registered Clinical Counsellors are not qualified to apply through the Special Access Program and should only engage with programs who meet the Health Canada requirements to conduct clinical trials and the SAP" [BCACC 2024].

Within sanctioned SAP-authorized programs, counsellors can serve as:

• The non-prescribing therapist in the two-therapist model required during MDMA administration. Health Canada's December 2022 expectations for clinical trials state that "during the phase in which the drug is being administered to the participants, there should be a minimum of two therapists present" [Health Canada 2022]. The Phase 3 MAPP1 and MAPP2 trials of MDMA-assisted therapy used a co-therapist team where the team had at least one licensed psychotherapy provider; master's-level practitioners participated in fidelity-validated cohorts [Mitchell et al. 2021; Mitchell et al. 2023; Wang et al. 2021].
• The integration therapist for SAP-authorized patients pursuing psilocybin or MDMA, where the prescribing physician has obtained SAP authorization and the counsellor is part of the supervised therapy program.
• The preparation therapist for patients pursuing SAP application through their physician. Counsellors can offer preparation psychotherapy that supports the patient's readiness without encouraging illegal use [BCCSW].

SAP authorization rates have declined. The Psychedelic Association of Canada documented an approximately 50 percent year-over-year decline in SAP approvals through 2025 [PsyCan 2025]. For counsellors, this means that even with appropriate training, opportunities to work with SAP-authorized psilocybin or MDMA patients are limited; KAT remains the more reliable clinical context for active PAT practice.

CCPA-approved and BCACC-recognized training programs in Canada

Canadian counsellors evaluating PAT training have several options. Recognition status with each accreditor matters for CE credit applicability.

TheraPsil — Fundamentals of Psilocybin-Assisted Psychotherapy (144.5 hours, $3,600 CAD online or $4,200–$4,450 in-person; 9–12 month cohort). CE accreditation: CPA, CCPA, OPQ — confirmed for 155 CE hours each. TheraPsil also offers MDMA-Assisted Psychotherapy training (122 hours, $3,600 online or $4,999 in-person; CE accreditation pending for MDMA track) and Prescriber Masterclasses (psilocybin = 8 Mainpro+ credits; MDMA pending). 2026 intakes are open.

Numinus — Practitioner Certification Pathway with three substance specializations (Ketamine, Psilocybin, MDMA). Structure: Free Intro (8 hours) → Fundamentals (10 weeks, $2,699 USD) → Applied (8 weeks, $1,499 USD) → Specialization (50–60 hours, $2,500 USD). CE accreditation: CPA, CCPA, OPQ, NBCC, ACE. Open to "regulated and non-regulated providers."

Roots to Thrive — Experiential Intensive Training (52 hours, $3,950 + $500 international surcharge; in-person Nanaimo, BC). Focused on KAT. Practicum hours have historically counted toward Vancouver Island University's PAT graduate certificate (now discontinued). Eligibility: clinicians with at least 2 years of mental-health experience; CCPA accreditation not confirmed.

Field Trip Health — PAT Training (~$1,500 CAD); explicitly not CE-accredited.

For counsellors whose practice is integration-focused (working with clients who received PAT elsewhere), ATMA CENA's Integrative (Essentials) Pathway — Foundations plus Advanced Safety & Support Practices (39 hours, $3,500) — is the more focused option.

Ready to explore the Clinical Pathway? See the full course structure, pricing, and next registration dates at /psychedelic-therapy-training/clinical/.

CE credits by designation: how training hours apply to renewal

Continuing-education recognition for counsellors in Canada works differently from the physician system.

CCPA (CCC renewal): CCPA requires 36 hours of continuing education per 3-year certification period. Effective January 2025, CCPA moved to a Continuing Education Trust System. Members renew without submitting CECs unless selected for audit; the 36-hour requirement is unchanged. As of January 2026, CCPA stops processing CEC applications outside of audit cycles. Members must retain CE records in case of audit (3 months' notice). CCPA-approved psychedelic training: TheraPsil (155 CE hours per program), Numinus (per module).

BCACC (RCC renewal): BCACC has no specific mandatory CE-hour threshold legislatively as of May 2026; professional development is encouraged under the Code of Ethics. Specific CE-hour mapping per training program varies; verify with BCACC for any program.

CRPO (RP renewal in Ontario): Continuing Competency Program — 40 hours of learning activities per 2-year cycle (minimum 20 hours per year), with at least one didactic and at least one experiential activity, plus 750 currency hours per rolling 3-year period.

OPQ (Quebec psychotherapy permit): 90 hours of CE in psychotherapy per 5-year period. OPQ has approved psychedelic harm-reduction and integration courses for CE credit including TheraPsil and Numinus offerings.

CACCF (addiction counselling): Offers a 2-hour psychedelic harm-reduction microcredential and approves selected psilocybin-assisted therapy workshops for 3 CE hours.

Scope-of-practice boundaries: what BCACC and CCPA expect before you begin

BCACC's 2024 Health Canada Guidelines on Psychedelic-Assisted Therapy document is the most explicit Canadian counsellor scope guidance. The verbatim "cannot" list:

"RCCs cannot procure, prescribe, dispense medications, or administer them to clients. Only regulated medical professionals and other regulated health professionals authorized through profession-specific regulation in their jurisdiction to prescribe, dispense and administer controlled drugs and substances can do this." [BCACC 2024]

The verbatim "can" list:

"RCCs can, with the appropriate training, be involved with the preparation of an individual or a group for the use of psychedelics, during the use of the psychedelic when the client is in an altered state (on a journey) and importantly, during the integration phase." [BCACC 2024]

BCCSW's parallel guidance for BC social workers states that registrants cannot administer, dispense, supervise administration, possess controlled substances, or "represent themselves as providing psychedelic-assisted psychotherapy." Permitted activities include psychoeducation about evidence-based mental health interventions, preparation counselling, integration counselling for past experiences, and supportive participation in authorized clinical trials or SAP programs as team members [BCCSW].

CRPO Ontario's developing guidance reminds RPs that they are "not authorized to prescribe medication, give advice about medication or communicate a diagnosis"; RPs expanding into PAT must collaborate with care-team members and seek consultation under Standard 2.1 [CRPO].

The Alberta exclusion in some provider models (such as ATMA CENA's coordinated care program) reflects the unregulated status of counselling therapists in Alberta. Until the College of Alberta Psychologists completes the regulatory framework for counselling therapists, Alberta counselling therapists may be excluded from certain coordinated care configurations that depend on statutory regulation. Counsellors working in Alberta should verify eligibility for any specific program before committing to training.

Supervision, practicum, and clinical readiness after certification

Completion of any training program does not authorize a counsellor to administer psychedelics — that authority does not exist for counsellors. Completion does establish competency to deliver the psychotherapy components of PAT under team supervision.

The published evidence on therapist training emphasizes supervised practicum as the most valued and most challenging component. Tai et al. (2021) evaluated a structured psilocybin therapist training program (n=65 across the United States, Canada, and Europe) using four components: online learning (over 20 hours of video), a five-day in-person workshop, minimum four supervised research sessions, and ongoing mentoring. Trainees rated "clinical training and engagement in participant care, under the guidance of experienced therapists" as "the most beneficial and challenging aspects of the training" [Tai et al. 2021]. The cohort included master's-level practitioners and counsellors alongside psychologists and psychiatrists.

ATMA CENA's Supervised Learning Lab (8 hours across 4 small-group sessions) is the cohort-based supervised practicum component for counsellors and other therapy clinicians. The optional KAT Immersive Experience (3 days in-person at the Calgary clinic) provides hands-on exposure to the full arc of a KAT session.

Ongoing supervision after independent practice begins is the professional standard. The Phase 3 MAPP1 trial protocol used 3 preparation sessions of 90 minutes each, 3 experimental sessions of 8 hours each, and 9 integration sessions per participant within a manualized two-therapist model that achieved 95 percent fidelity across 14 North American sites [Mitchell et al. 2021; Wang et al. 2021]. Counsellors building PAT practice should plan for case consultation, peer supervision, and continued CE.

Joining a supervised clinic model: how counsellors work within PAT teams

Trained counsellors integrate into PAT delivery primarily through three structures: as team members of an established clinical-trial site, through SAP-authorized programs led by a physician or nurse practitioner, or through a structured clinic network model that handles the medical and regulatory infrastructure.

Once trained, the coordinated care model lets counsellors bring psychedelic-assisted therapy into their existing counselling practice with ATMA CENA handling the medical infrastructure. Learn how coordinated care works.

Frequently asked questions

Can a Canadian Certified Counsellor (CCC) administer ketamine?

No. CCCs cannot administer, dispense, or prescribe any controlled substance, including ketamine. CCCs can serve as preparation, support, and integration therapists within a multidisciplinary team led by a physician or nurse practitioner who holds prescribing authority [BCACC 2024 — applicable principles].

Can a Registered Clinical Counsellor (RCC) apply for psilocybin via SAP?

No. BCACC's 2024 guidance is explicit that "Registered Clinical Counsellors are not qualified to apply through the Special Access Program." SAP applications must be submitted by a licensed prescriber (physician or nurse practitioner with controlled-substance authority).

Do CCPA-approved CE hours from psychedelic training programs count toward CCC renewal?

Yes, in alignment with CCPA's 36-hour-per-3-year requirement. As of January 2025, members do not submit CECs at renewal under the Continuing Education Trust System but must maintain records in case of audit. TheraPsil's psilocybin and MDMA training programs are CCPA-approved for 155 CE hours each. Numinus's pathway is also CCPA-approved.

Are counsellors eligible for ATMA CENA's training pathways?

Yes. The Foundations course explicitly lists clinical counsellors as eligible. The Clinical Pathway is the primary route for counsellors who will deliver psychotherapy components of PAT. The Supervised Learning Lab and the KAT Immersive Experience explicitly include counsellors in their eligible audiences. The Integrative (Essentials) Pathway is appropriate for counsellors focused on integration-only work.

Why are some counsellor designations excluded from coordinated care in Alberta?

Counselling therapists in Alberta are currently in transition: the College of Alberta Psychologists is the designated future regulator, but the regulatory framework is still pending as of May 2026. Some clinic network models require regulated-professional status. Verify current eligibility with ATMA CENA before committing to a pathway if you practice in Alberta.

What is the difference between the Clinical and Integrative pathways for counsellors?

The Clinical Pathway prepares clinicians to participate in the full arc of PAT including dosing-day support; it requires deeper clinical-skill development (Applied Clinical Practice, 55 hours; plus Supervised Learning Lab). The Integrative Pathway prepares clinicians for preparation and integration roles only — appropriate for counsellors whose practice will not include dosing-day involvement. The pathway choice depends on your scope, your provincial framework, and your desired role.

Can counsellors work with patients in MDMA-assisted therapy clinical trials?

Within the two-therapist model used in the MAPP1 and MAPP2 Phase 3 trials, the team typically includes one licensed psychotherapy provider and a co-therapist; master's-level practitioners (including counsellors) have participated in fidelity-validated cohorts [Mitchell et al. 2021; Wang et al. 2021]. Team composition varies by trial site and its own credential requirements.

What does the BCACC 2024 guidance say about RCC scope in PAT?

BCACC explicitly distinguishes what RCCs cannot do (procure, prescribe, dispense, administer; apply through SAP) from what they can do (preparation, in-session support during the journey, integration — all with appropriate training and within sanctioned programs). The guidance emphasizes multidisciplinary team practice and rigorous training, oversight, and supervision [BCACC 2024].

How do I choose between TheraPsil, Numinus, and ATMA CENA training?

Choice depends on substance focus, format preference, and credential alignment. TheraPsil specializes in psilocybin and MDMA with deep SAP-pathway content. Numinus offers ketamine, psilocybin, and MDMA tracks with broad CCPA/CPA/OPQ/NBCC accreditation. ATMA CENA's pathways are anchored in Canadian regulatory frameworks and offer in-person experiential components alongside online didactic delivery, with counsellor designations explicitly listed in eligibility. Compare CE accreditation status, total program hours, and post-training practice integration before deciding.

What happens after I complete training?

Trained counsellors join PAT delivery through clinical-trial sites, SAP-authorized programs, or structured clinic-network models such as ATMA CENA's coordinated care. Ongoing supervision and continuing CE are professional expectations. Many counsellors continue building PAT competencies across multiple substance modalities and integration frameworks — including PHRI (Psychedelic Harm Reduction and Integration) and EMBARK — over years rather than weeks [Gorman et al. 2021; Brennan & Belser 2022].

Sources

1. Health Canada (2022). Notice to stakeholders: SAP psychedelic-assisted psychotherapy. https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/announcements/requests-special-access-program-psychedelic-assisted-psychotherapy.html
2. Health Canada (2022). Risk-management measures for clinical trials. https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/announcements/expectations-risk-management-measures-clinical-trials-psychedelic-assisted-psychotherapy.html
3. BCACC (2024). Health Canada Guidelines on Psychedelic-Assisted Therapy (October 2024 / November 2025 update). https://bcacc.ca/wp-content/uploads/2025/11/Health-Canada-Guidelines-on-Psychedelic-Assisted-Therapy-2024-October.pdf
4. BCCSW. Practice Guidance: Psychedelic-Assisted Psychotherapy and Scope of Practice. https://bccsw.ca/for-registrants/standards-scope-of-practice/practice-guidance/practice-guidance-document-for-registrants-psychedelic-assisted-psychotherapy/
5. CRPO. Psychedelic-Assisted Psychotherapy Resource. https://crpo.ca/resource-articles/psychedelic-assisted-psychotherapy/
6. CAP (2025). Psychedelic-Assisted Psychotherapy Practice Guideline (June 2025). https://www.cap.ab.ca/Portals/0/adam/Content/fQCpza4q7EGXC_psrgnCvA/Link/Psychedelic-Assisted%20Psychotherapy%20-%20June%202025.pdf
7. CPSA (2026). Ketamine Prescribing, Administration and Oversight Expectations (March 2026). https://cpsa.ca/wp-content/uploads/2026/03/CPSA_Ketamine-Guidance_March-2026.pdf
8. CPSBC (2025). Interim Guidance: Ketamine Administration via IM/Oral/SL/IN Routes (Version 1.3, August 2025). https://www.cpsbc.ca/files/pdf/IG-Ketamine-Administration-via-Intramuscular-Oral-Sublingual-Intranasal-Routes.pdf
9. CPSM (2026). Ketamine: What Prescribers and Pharmacists Need to Know (January 2026). https://www.cpsm.mb.ca/news/ketamine-what-prescribers-and-pharmacists-need-to-know
10. CCPA. Continuing Education. https://www.ccpa-accp.ca/continuing-education/
11. KATA Canada. Outpatient Use of Ketamine for Mental Health Conditions Practice Standards (December 2023). https://katacanada.org/wp-content/uploads/2024/02/KATA__OMA_Psychedelic_MIG_Practice_Standards_Recommendations_Outpatient.pdf
12. PsyCan (2025). Sharp decline in Health Canada SAP approvals. https://psychedelicscanada.org/media/2025/09/psycan-discovers-sharp-decline-in-health-canada-approvals-for-doctors-seeking-legal-psychedelic-therapy-for-patients
13. Flückiger, C., Del Re, A.C., Wampold, B.E. & Horvath, A.O. (2018). The alliance in adult psychotherapy: A meta-analytic synthesis. Psychotherapy, 55(4), 316–340. https://pubmed.ncbi.nlm.nih.gov/29792475/
14. Murphy, R. et al. (2022). Therapeutic alliance and rapport modulate responses to psilocybin assisted therapy for depression. Frontiers in Pharmacology, 12, 788155. https://pmc.ncbi.nlm.nih.gov/articles/PMC9009076/
15. Levin, A.W. et al. (2024). The therapeutic alliance between study participants and intervention facilitators is associated with acute effects and clinical outcomes in a psilocybin-assisted therapy trial for major depressive disorder. PLOS ONE, 19(3), e0300501. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0300501
16. Phelps, J. (2017). Developing Guidelines and Competencies for the Training of Psychedelic Therapists. Journal of Humanistic Psychology, 57(5), 450–487. https://journals.sagepub.com/doi/abs/10.1177/0022167817711304
17. Kamilar-Britt, P., Gordis, E.B. & Earleywine, M. (2023). The therapeutic alliance in psychedelic-assisted psychotherapy. Psychedelic Medicine, 1(4), 262–266. https://pmc.ncbi.nlm.nih.gov/articles/PMC11658648/
18. Gorman, I., Nielson, E.M., Molinar, A., Cassidy, K. & Sabbagh, J. (2021). Psychedelic Harm Reduction and Integration: A transtheoretical model. Frontiers in Psychology, 12, 645246. https://pmc.ncbi.nlm.nih.gov/articles/PMC8008322/
19. Brennan, W. & Belser, A.B. (2022). Models of Psychedelic-Assisted Psychotherapy: Introduction to EMBARK. Frontiers in Psychology, 13, 866018. https://www.frontiersin.org/journals/psychology/articles/10.3389/fpsyg.2022.866018/full
20. Cavarra, M. et al. (2022). Psychedelic-assisted psychotherapy: A systematic review of associated psychological interventions. Frontiers in Psychology, 13, 887255. https://pmc.ncbi.nlm.nih.gov/articles/PMC9226617/
21. Hartogsohn, I. (2016). Set and setting, psychedelics and the placebo response. Journal of Psychopharmacology, 30(12), 1259–1267. https://pubmed.ncbi.nlm.nih.gov/27852960/
22. Haijen, E.C.H.M. et al. (2018). Predicting Responses to Psychedelics: A Prospective Study. Frontiers in Pharmacology, 9, 897. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2018.00897/full
23. Drozdz, S.J. et al. (2022). Ketamine Assisted Psychotherapy: A Systematic Narrative Review. Journal of Pain Research, 15, 1691–1706. https://pmc.ncbi.nlm.nih.gov/articles/PMC9207256/
24. Yermus, R. et al. (2024). Ketamine-Assisted Psychotherapy Provides Lasting and Effective Results at 3 and 6 Months. Psychedelic Medicine, 2(2), 87–95. https://pmc.ncbi.nlm.nih.gov/articles/PMC11613527/
25. Wilkinson, S.T. et al. (2017). Cognitive Behavior Therapy May Sustain Antidepressant Effects of IV Ketamine. Psychotherapy and Psychosomatics, 86(3), 162–167. https://pmc.ncbi.nlm.nih.gov/articles/PMC5516265/
26. Tai, S.J. et al. (2021). Therapist Training Program for Psilocybin Therapy. Frontiers in Psychiatry, 12, 586682. https://pmc.ncbi.nlm.nih.gov/articles/PMC7908919/
27. Mitchell, J.M. et al. (2021). MDMA-assisted therapy for severe PTSD: Phase 3 MAPP1. Nature Medicine, 27, 1025–1033. https://pmc.ncbi.nlm.nih.gov/articles/PMC8205851/
28. Mitchell, J.M. et al. (2023). MDMA-assisted therapy for moderate to severe PTSD: Phase 3 MAPP2. Nature Medicine, 29, 2473–2480. https://www.nature.com/articles/s41591-023-02565-4
29. Wang, J.B. et al. (2021). Scaling up: Multisite MDMA-AT fidelity. Journal of Humanistic Psychology. https://journals.sagepub.com/doi/full/10.1177/00221678211023663
30. Modlin, N.L. et al. (2024). Trauma-Informed Care in Psychedelic Therapy Research. Neuropsychiatric Disease and Treatment, 20, 109–135. https://pmc.ncbi.nlm.nih.gov/articles/PMC10807282/

Related articles in this cluster

• Psychedelic Therapy Training in Canada
• Ketamine-Assisted Psychotherapy Training in Canada
• Psychedelic Therapy Training for Physicians
• Psychedelic Therapy Training for Psychotherapists
• Psychedelic Therapy Training for Psychologists
• Psychedelic Therapy Training Cost in Canada
• Which Psychedelic Therapy Training Pathway Is Right for Me?
• How to Become a Psychedelic Therapist in Canada
• How to Get Psychedelic Therapy Certification in Canada
• Clinical Pathway
• Integrative (Essentials) Pathway
• Find care near you
• Practitioner FAQs

Last updated: 2026-05-05. Article is reviewed every 6 months.